Determination of the anticoagulant effects of new oral anticoagulants: An unmet need

Expert Review of Hematology

Volumn 5, Issue 1, 2012, Pages 107-113

  Harenberg, Job ^a   Marx, Svetlana ^a   Erdle, Sandra ^a   Krämer, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

activated partial thromboplastin time; apixaban; atrial fibrillation; chromogenic substrate assays; dabigatran; oral anticoagulants; prothrombin time; prothrombinase induced clotting time; rivaroxaban; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; CHROMOGENIC SUBSTRATE; ECARIN; THROMBOPLASTIN;

ARTICLE; GLOMERULUS FILTRATION; HIP ARTHROPLASTY; HUMAN; KIDNEY FUNCTION; KNEE ARTHROPLASTY; LABORATORY TEST; PRIORITY JOURNAL; PROTHROMBIN TIME; STANDARDIZATION; THROMBOPLASTIN TIME; VENOUS THROMBOEMBOLISM; ANTICOAGULATION; BLOOD CLOTTING; DOSE KIDNEY FUNCTION RELATION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; PARTIAL THROMBOPLASTIN TIME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; THIOPHENES; THROMBOEMBOLISM;

EID: 84856303923     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.79     Document Type: Article

References (25)

1. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133(Suppl. 6), S160-S198 (2008).
2. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133(Suppl. 6), S546-S592 (2008).
3. Harenberg J, Marx S, Wehling M et al. New anticoagulants - promising and failed developments. Br. J. Pharmacol. 165(2), 363-372 (2012).
4. Harenberg J. New anticoagulants in atrial fibrillation. Semin. Thromb. Hemost. 35(6), 574-585 (2009).
5. Le Grand M, Mateo J, Aribaut A et al. The use of dabigatran in elderly patients. Arch. Int. Med. 171(14), 1285-1286 (2011).
6. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J. Thromb. Haemost. 8(4), 621-626 (2010).
7. Samama MM, Martinoli JL, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb. Haemost. 103(4), 815-825 (2010).
8. Asmis LM, Alberio L, Angelillo-Scherrer A et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thromb. Res. doi:10.1016/j.thromres.2011.06.031 (2011) (Epub ahead of print).
9. Harenberg J, Krämer R, Giese C et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J. Thromb. Thrombolys. 32(3), 267-271 (2011).
10. Harenberg J, Marx M, Krämer R et al. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul. Fibrinolysis 22(8), 637-641 (2011).
11. Samama M, Contant G, Spiro T et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin. Appl. Thromb. Hemost. (2012) (In press).
12. Calatzis A, Spannagl M, Gempeler- Messina P et al. The prothrombinase-induced clotting time, a new technique for the monitoring of anticoagulants. Haemostasis 30(Suppl. 2), S172-S174 (2000).
13. Harenberg J, Giese C, Hagedorn A et al. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin. Thromb. Hemost. 33(5), 503-507 (2007). (Pubitemid 47105740)
14. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb. Res. 123(2), 396-403 (2008).
15. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin. Pharmac. 48(1), 1-22 (2009).
16. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(9), 883-891 (2011).
17. Granger CB, Alexander JH, McMurray JJ et al. The ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981-992 (2011).
18. Jakobs JM, Stessman J. New anticoagulant drugs in elderly patients - is caution necessary? Arch. Int. Med. 171(14), 1287-1288 (2011).
19. Tulner LR, Van Campen JP, Kuper IM et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Ageing 27(1), 39-50 (2010).
20. Pengo V, Crippa L, Falanga A et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian federation of thrombosis centers (FCSA). Thromb. Haemost. 106(5), 868-876 (2011).
21. Takeuchi S, Wada K, Nagatani K et al. Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients. Acta Neurochir. 154(1), 87 (2012).
22. Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Ann. Pharmacother. 45(7-8), e40 (2011).
23. DeRemer CE, Guiral JS, Thornton JW, Sorrentino RA. Dabigatran falsely elevates point of care international normalized ratio results. Am. J. Med. 124(9), 5-6 (2011).
24. Liesenfeld KH, Schäfer HG, Trocóniz IF et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br. J. Clin. Pharmacol. 62(5), 527-537 (2006). (Pubitemid 44571573)
25. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb. Res. 127(5), 457-465 (2011).